EGFR and cancer: Individual diver gene mutations were previously identified from tumor tissue demonstrated to promote (such as KRAS [46], TP53 [47], PTCH1 [48]) or weaken (such as JAK1/2 [49], EGFR [50], PTEN [51]) the response to immune checkpoint inhibitor therapy in cancer patients.